| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA705: Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | atezolizumab (Tecentriq®) |
| Formulation | intravenous infusion |
| Reference number | 4215 |
| Indication | Monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 22/04/2021 |
| NICE guidance | TA705: Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer |